Jump to main content
Jump to site search
PLANNED MAINTENANCE Close the message box

Scheduled maintenance work on Wednesday 22nd May 2019 from 11:00 AM to 1:00 PM (GMT).

During this time our website performance may be temporarily affected. We apologise for any inconvenience this might cause and thank you for your patience.

Issue 4, 2014
Previous Article Next Article

Emerging classes of armed antibody therapeutics against cancer

Author affiliations


Monoclonal antibodies represent the largest and fastest growing type of biopharmaceuticals. Their commercial and clinical success has fueled research activities aiming to improve safety and efficacy. In oncology, there is a trend towards the development of ‘armed’ antibody products, in which the immunoglobulin moiety serves for the selective in vivo pharmacodelivery of bioactive payloads such as cytotoxic drugs, bispecific antibodies, radionuclides or cytokines to sites of disease, thereby sparing healthy tissues. In this article, we review some of the most advanced preclinical and clinical activities in the field of armed antibodies and present a personal perspective on the opportunities and challenges associated with the use of this type of anti-cancer therapeutics.

Graphical abstract: Emerging classes of armed antibody therapeutics against cancer

Back to tab navigation

Publication details

The article was received on 27 Nov 2013, accepted on 18 Dec 2013 and first published on 07 Jan 2014

Article type: Review Article
DOI: 10.1039/C3MD00360D
Med. Chem. Commun., 2014,5, 408-431

  •   Request permissions

    Emerging classes of armed antibody therapeutics against cancer

    C. Hess, D. Venetz and D. Neri, Med. Chem. Commun., 2014, 5, 408
    DOI: 10.1039/C3MD00360D

Search articles by author